Cognition Therapeutics Inc (CGTX) concluded trading on Tuesday at a closing price of $0.65, with 2.85 million shares of worth about $1.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.47% during that period and on December 24, 2024 the price saw a gain of about 5.54%. Currently the company’s common shares owned by public are about 40.81M shares, out of which, 35.21M shares are available for trading.
Stock saw a price change of 43.99% in past 5 days and over the past one month there was a price change of 53.14%. Year-to-date (YTD), CGTX shares are showing a performance of -64.59% which decreased to -61.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.34 but also hit the highest price of $2.95 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 6.74 million. The stock is currently trading 35.62% above its 20-day simple moving average (SMA20), while that difference is up 32.87% for SMA50 and it goes to -46.90% lower than SMA200.
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 40.81M outstanding shares and institutions hold larger chunk of about 10.36% of that.
The stock has a current market capitalization of $28.41M and its 3Y-monthly beta is at 1.13. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 2.11 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 38.79% while standing at 17.49% over the month.
Stock’s fiscal year EPS is expected to drop by -0.78% while it is estimated to increase by 12.08% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 19, 2024 offering a Buy rating for the stock and assigned a target price range of between $1 and $1.50 to it. On November 03, 2021, Oppenheimer Initiated their recommendations, while on November 03, 2021, B. Riley Securities Initiated their ratings for the stock with a price target of $27.
